Cotadutide acetate manufacturers
|
| | Cotadutide acetate Basic information |
| Product Name: | Cotadutide acetate | | Synonyms: | Cotadutide acetate;Cotadutide acetate (1686108-82-6 Free base);MEDI0382 acetate;Cotadutide | | CAS: | 1686108-82-6 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Cotadutide acetate Structure]() |
| | Cotadutide acetate Chemical Properties |
| solubility | Water: Slightly soluble: 0.1-1 mg/ml | | form | Solid | | color | White to light yellow | | Sequence | 1'-{palmtoyl-Glu}; His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Lys-Ser-Glu-Tyr-Leu-Asp-Ser-Glu-Arg-Ala-Arg-Asp-Phe-Val-Ala-Trp-Leu-Glu-Ala-Gly-Gly (Amide bridge: 1'-{palmtoyl-Glu}-Lys10) |
| | Cotadutide acetate Usage And Synthesis |
| Uses | Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D)[1][2][3]. | | in vivo | Cotadutide (10nmol/kg, s.c., once) suppresses food intake in DIO mice relative to vehicle‐treated controls[1].
Cotadutide (10 or 30nmol/kg, s.c., once daily for 14-16 weeks) reduces body weight in DIO mice[1].
Cotadutide (30 nmol/kg, s.c., once a day for 6 weeks) reduces hepatic fibrosis and inflammation in in ob/ob AMLN NASH mice[2]. | Animal Model: | Diet-induced obesity (DIO) mice[1] | | Dosage: | 10nmol/kg | | Administration: | Subcutaneousinjection (s.c.) | | Result: | Showed a redction of food intake in mice after an acute administration. |
| Animal Model: | Diet-induced obesity (DIO) mice[1] | | Dosage: | 10 or 30nmol/kg | | Administration: | Subcutaneousinjection (s.c.) | | Result: | Reduced body weight and food intake, and improved glucose tolerance in DIO mice. |
| | References | [1] Henderson SJ,et al. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates.Diabetes Obes Metab. 2016 Dec;18(12):1176-1190. DOI:10.1111/dom.12735
[2] Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis. Nat Metab. 2020 May;2(5):413-431. DOI:10.1038/s42255-020-0209-6 |
| | Cotadutide acetate Preparation Products And Raw materials |
|